Leukocyte- and Platelet-Rich Fibrin in the Surgical Treatment of Medication-related Osteonecrosis of the Jaw
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Surgery with the use of L-PRF, Standard surgery.
- Who it may be relevant to
- Registry conditions: Osteonecrosis of the Jaw. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Use of Leukocyte- and Platelet-Rich Fibrin in the Surgical Treatment of Medication-related Osteonecrosis of the Jaw: a Randomized Controlled Trial
Overview
Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious side-effect of antiresorptive therapies used in the management of bone diseases, such as osteoporosis or bone metastases. A surgical management can lead to a resolution of the disease, but with perfectible results. For this purpose, the use of autologous platelet concentrates (APC) can be useful. With this study, researchers aim to demonstrate the efficacy of L-PRF (Leukocyte- and Platelet-Rich Fibrin) as an adjunct to the surgical treatment of MRONJ in terms of wound healing.
Detailed description
Resulting in bone loss, infection, pain or discomfort, the presence of MRONJ decreases the quality of life of patients. There isn't any consensus about the treatment modalities for MRONJ, nor about its main goals. Traditionally, therapeutics only aimed to control and prevent the progression of the disease, but recent studies suggest that a whole resolution can currently be expected, especially from surgical therapies. These, when indicated, are not only intended for the removal of the pathological tissue, but above all for an hermetic mucosal healing, preventing secondary infection of the underlying bone.
The L-PRF (Leukocyte- and Platelet-Rich Fibrin) is a second-generation APC, produced in a strictly autologous way, by extemporaneous centrifugation of the patient's own blood. A fibrin clot, containing leukocytes and thrombocytes, is thereby isolated and transformed into membranes by compression. Their appliance to the surgical site allows a slow release of growth factors and cytokines with a positive effect on the revascularization of the wound.
Unfortunately, scientific evidence of their efficiencies is lacking. Therefore, a protocol of randomized clinical trial is proposed, aimed at evaluating the effect of the adjunction of APC to surgical procedures on the complete mucosal healing and thus the resolution of the MRONJ.
The control treatment strategy consists of the complete removal of the necrotic bone, in bleeding margins, followed by a tension-free and hermetic closure. In the test group, suturing will be preceded by the application of L-PRF membranes under the wound.
Patients will be followed for 6 months, during which the maintain of wound closure will be monitored. An evaluation of pain, health-related quality of life and oral health-related quality of life, will also be reported, such as the occurrence of adverse events.
Interventions
- Procedure Surgery with the use of L-PRF
The study protocol is the same as the standard surgery one but with additional use of L-PRF membranes - Procedure Standard surgery
The standard surgical treatment, taking place in the operating room under general anesthesia
Primary outcome measures
- Evaluation of the efficacy of the use of L-PRF during the surgical treatment of MRONJ, compared to surgical treatment alone, on complete mucosal healing. [Time frame: 6 months postoperatively]
Secondary outcome measures (12)
- MRONJ stage - Month 1 [Time frame: 1 month postoperatively]
- MRONJ stage - Month 3 [Time frame: 3 months postoperatively]
- MRONJ stage - Month 6 [Time frame: 6 months postoperatively]
- the postoperative pain - Month 1 [Time frame: 1 month postoperatively]
- the postoperative pain - Month 3 [Time frame: 3 months postoperatively]
- the postoperative pain - Month 6 [Time frame: 6 months postoperatively]
- health-related quality of life - Month 1 - World Health Organization Quality of Life WHOQOL-BREF [Time frame: 1 month postoperatively]
- health-related quality of life - Month 1 - OHIP-14 [Time frame: 1 month postoperatively]
- health-related quality of life - Month 3 WHOQOL-BREF [Time frame: 3 months postoperatively]
- health-related quality of life - Month 3 Oral health-related quality OHIP-14 [Time frame: 3 months postoperatively]
- health-related quality of life - Month 6 WHOQOL-BREF [Time frame: 6 months postoperatively]
- health-related quality of life - Month 6 - OHIP-14 [Time frame: 6 months postoperatively]
Eligibility criteria
Inclusion criteria
- MRONJ requiring surgical treatment according to AAOMS criteria (stage 2 or 3; failure of first-line treatments; sequestration of a necrotic bone block), the resection of which needs general anesthesia;
- Affiliates or beneficiaries of a social security scheme.
- Having given free and informed written consent.
Exclusion criteria
- Presence of a maxillo-mandibular neoplastic lesion;
- Presence of several MRONJ lesions;
- History of cervico-facial radiotherapy;
- Contraindication to general anesthesia;
- Reduced life expectancy (estimated at less than 6 months).
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
France · 7 centers
- University Hospital - Centre François-Xavier Michelet — Bordeaux
- University Hospital - Groupe hospitalier Pellegrin — Bordeaux
- University Hospital — Limoges
- University Hospital Gui de CHAULIAC — Montpellier
- University Hospital Pitié-Salpêtrière — Paris
- University Hospital — Toulouse
- University Hospital — Toulouse
Identifiers
NCT: NCT06419010 · RC31/21/0165